• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Oral cancer-overexpressed protein 1 (ORAOV1)

ACP13890

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP13890 Target NameORAOV1
Target SynonymsLTO1; ORAOV1; TAOS1Protein LTO1 homolog; Oral cancer-overexpressed protein 1; Tumor-amplified and overexpressed sequence 1FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range2-137
Protein LengthFull Length of Mature ProteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ8WV07
Background Information
  • Uniprot Id

    Q8WV07

  • Target Species

    Human

  • Target Name

    LTO1

  • Target Full Name

    Protein LTO1 homolog

  • Target Function

    The complex LTO1:YAE1 functions as a target specific adapter that probably recruits apo-ABCE1 to the cytosolic iron-sulfur protein assembly (CIA) complex machinery. May be required for biogenesis of the large ribosomal subunit and initiation of translation. May play a role in the regulation of proline metabolism and ROS production.

  • Target Subcellular Location

    Nucleus.

  • Target Protein Families

    ORAOV1 family

  • Target Tissue Specificity

    Widely expressed. Highly expressed in placenta, kidney and skeletal muscle.

  • Target Synonyms

    LTO1; ORAOV1; TAOS1Protein LTO1 homolog; Oral cancer-overexpressed protein 1; Tumor-amplified and overexpressed sequence 1

Inquire Recombinant Human Oral cancer-overexpressed protein 1 (ORAOV1) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification